Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19

Few effective therapeutic options are available for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. IL-6 receptor blockade has been proposed as one potential therapeutic strategy, and more than 40 clinical trials of anti-IL-6 receptor antibodies (including tocilizumab and sarilumab) in the setting of SARS-CoV-2 infection are underway (appendix p 2). Early…

Read the full article here

Related Articles